Quantum-Si Incorporated, a company pioneering next-generation
semiconductor chip-based proteomics, announced today the
appointment of Marijn Dekkers, Ph.D. and Ruth Fattori to its Board
of Directors. Both Dr. Dekkers and Ms. Fattori have agreed to
continue to serve on the Board of Directors of the combined company
subsequent to the closing of the previously announced business
combination between Quantum-Si and HighCape Capital Acquisition
Corp (Nasdaq: CAPA).
“We are positioning Quantum-Si to have the best chance of
delivering on the promise of next-generation proteomics by
continuing to enhance our leadership team and board of directors,
including the addition of Dr. Marijn Dekkers, former CEO of Bayer
AG and Thermo Fisher Scientific, and Ms. Ruth Fattori, former
Executive Vice President and Chief Human Resources Officer of
PepsiCo,” said Dr. Jonathan Rothberg, Founder and Chairman of
Quantum-Si. “Much like our team gave the world next-generation DNA
sequencing, Marijn was instrumental in giving the world the last
generation of protein analysis and Ruth was vital in scaling global
human resource functions to build strong organizational structures
and support talent acquisition. Collectively, their skill sets are
well positioned to help us navigate this transition as we give the
world next-generation protein sequencing.”
Dr. Dekkers is Founder and Chairman of Novalis LifeSciences LLC,
a life sciences industry investment and advisory firm. From 2010 to
2016, Dr. Dekkers served as CEO of Bayer AG in Leverkusen, Germany,
and from 2002 to 2009, he was CEO of Thermo Fisher Scientific. Dr.
Dekkers currently serves on the board of directors of the
Foundation for the National Institutes of Health, Georgetown
University, Quanterix Corporation, and Cerevel Therapeutics, Inc.
Dr. Dekkers received his Ph.D. and M.S. in chemical engineering
from the University of Eindhoven and his bachelor’s degree in
chemistry from the Radboud University, both in the Netherlands.
“The potential of next-generation protein sequencing could have
a significant impact on drug discovery, academic research, and
diagnostics beyond what is available today,” said Dr. Dekkers. “I
look forward to leveraging my experience at Bayer and Thermo Fisher
Scientific to help Quantum-Si see its vision through.”
Ms. Fattori is a Managing Partner of Pecksland Partners, LLC
where she advises CEOs and senior executives on succession
planning, talent development, and other human resources issues. She
also serves as a Senior Advisor at the Boston Consulting Group
supporting its People and Organization Practice and CEO Advisory
program. Most recently, she served as Executive Vice President and
Chief Human Resources Officer of PepsiCo Inc. In this role, Ruth
was responsible for the company’s global HR function including
talent acquisition, leadership development, learning, compensation
and benefits, organizational management, and HR operations. Ruth
and her team also partnered closely with PepsiCo’s sectors and
business units to advance organizational health as well as
diversity, inclusion, and engagement. She previously served as
Executive Vice President and Chief Administrative Officer for
MetLife and also served as Chair of MetLife Foundation. Earlier,
she was the Chief Human Resources Officer at Motorola. Ruth holds a
B.S. in mechanical engineering from Cornell University.
“I’m pleased to be joining the board of Quantum-Si to partner
with a highly-experienced and ambitious team in its pursuit to make
an impact on innovation and health with next-generation protein
sequencing,” said Ms. Fattori. “I look forward to applying my
expertise in building out global organizational functions with an
eye on high-caliber talent, diversity, inclusion, and
engagement.”
About Quantum-Si
Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused
on revolutionizing the growing field of proteomics. The company’s
suite of technologies are powered by a first-of-its-kind
semiconductor chip designed to enable single-molecule
next-generation protein sequencing, and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing.
On February 18, 2021, Quantum-Si and HighCape Capital
Acquisition Corp. (Nasdaq: CAPA) (“HighCape”), a healthcare-focused
special purpose acquisition company sponsored by leading healthcare
growth-equity investment firm, HighCape Capital LP, announced a
proposed business combination.
Important Information About the Proposed Business Combination
and Where to Find It
In connection with the proposed business combination between
HighCape and Quantum-Si (the “Business Combination”), HighCape has
filed with the Securities and Exchange Commission (the “SEC”) a
registration statement on Form S-4 (the “Registration Statement”),
which includes a preliminary proxy statement/prospectus and, as
amended, will include a definitive proxy statement/prospectus, and
certain other related documents, which will be both the proxy
statement to be distributed to holders of shares of HighCape’s
common stock in connection with HighCape’s solicitation of proxies
for the vote by HighCape’s stockholders with respect to the
Business Combination and other matters as may be described in the
Registration Statement, as well as the prospectus relating to the
offer and sale of the securities of HighCape to be issued in the
Business Combination. HighCape’s stockholders and other interested
persons are advised to read the preliminary proxy
statement/prospectus included in the Registration Statement and the
amendments thereto and the definitive proxy statement/prospectus,
when available, as well as other documents filed with the SEC in
connection with the Business Combination, as these materials will
contain important information about the parties to the Business
Combination Agreement and the Business Combination. After the
Registration Statement is declared effective, the definitive proxy
statement/prospectus and other relevant materials for the Business
Combination will be mailed to stockholders of HighCape as of a
record date to be established for voting on the Business
Combination and other matters as may be described in the
Registration Statement. Stockholders will also be able to obtain
copies of the preliminary proxy statement/prospectus, the
definitive proxy statement/prospectus, and other documents filed
with the SEC that will be incorporated by reference therein,
without charge, once available, at the SEC’s web site at
www.sec.gov, or by directing a request to: HighCape Capital
Acquisition Corp., 452 Fifth Avenue, 21st Floor, New York, NY
10018, Attention: Kevin Rakin, or to
info@HighCapeacquisition.com.
Participants in the Solicitation
HighCape and its directors and executive officers may be deemed
participants in the solicitation of proxies from HighCape’s
stockholders with respect to the Business Combination. A list of
the names of those directors and executive officers and a
description of their interests in HighCape is contained in the
Registration Statement for the Business Combination, and will be
available free of charge at the SEC’s web site at www.sec.gov, or
by directing a request to HighCape Capital Acquisition Corp., 452
Fifth Avenue, 21st Floor, New York, NY 10018, Attention: Kevin
Rakin, or to info@HighCapeacquisition.com. Additional information
regarding the interests of such participants is contained in the
Registration Statement.
Quantum-Si and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
stockholders of HighCape in connection with the Business
Combination. A list of the names of such directors and executive
officers and information regarding their interests in the Business
Combination is contained in the Registration Statement.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. Quantum Si’s
actual results may differ from its expectations, estimates, and
projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation,
Quantum-Si’s expectations with respect to future performance,
development of products and services, potential regulatory
approvals, and anticipated financial impacts and other effects of
the Business Combination, the satisfaction of the closing
conditions to Business Combination, the timing of the completion of
the Business Combination, and the size and potential growth of
current or future markets for the combined company’s future
products and services. These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from those discussed in the
forward-looking statements. Most of these factors are outside
HighCape’s and Quantum-Si’s control and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: the occurrence of any event, change, or other
circumstances that could give rise to the termination of the
Business Combination Agreement; the outcome of any legal
proceedings that may be instituted against HighCape and Quantum-Si
following the announcement of the Business Combination Agreement
and the transactions contemplated therein; the inability to
complete the Business Combination, including due to failure to
obtain approval of the stockholders of HighCape and Quantum-Si,
certain regulatory approvals, or satisfy other conditions to
closing in the Business Combination Agreement; the occurrence of
any event, change, or other circumstance that could give rise to
the termination of the Business Combination Agreement or could
otherwise cause the transaction to fail to close; the impact of
COVID-19 on Quantum-Si’s business and/or the ability of the parties
to complete the Business Combination; the inability to obtain or
maintain the listing of the combined company’s shares of Class A
common stock on The Nasdaq Stock Market following the Business
Combination; the risk that the Business Combination disrupts
current plans and operations as a result of the announcement and
consummation of the Business Combination; the ability to recognize
the anticipated benefits of the Business Combination, which may be
affected by, among other things, competition and the ability of
Quantum-Si to grow and manage growth profitably and retain its key
employees; costs related to the Business Combination; changes in
applicable laws or regulations; the ability of the combined company
to raise financing in the future; the success, cost and timing of
Quantum-Si’s and the combined company’s product development
activities; the potential attributes and benefits of Quantum-Si’s
and the combined company’s products and services; Quantum-Si’s and
the combined company’s ability to obtain and maintain regulatory
approval for their products, and any related restrictions and
limitations of any approved product; Quantum-Si’s and the combined
company’s ability to identify, in-license or acquire additional
technology; Quantum-Si’s and the combined company’s ability to
maintain Quantum-Si’s existing license, manufacture and supply
agreements; Quantum-Si’s and the combined company’s ability to
compete with other companies currently marketing or engaged in the
development of products and services that Quantum-Si is developing;
the size and growth potential of the markets for Quantum-Si’s and
the combined company’s future products and services, and each of
their ability to serve those markets, either alone or in
partnership with others; the pricing of Quantum-Si’s and the
combined company’s products and services following anticipated
commercial launch; Quantum-Si’s and the combined company’s
estimates regarding future expenses, future revenue, capital
requirements and needs for additional financing; Quantum-Si’s and
the combined company’s financial performance; and other risks and
uncertainties indicated from time to time in HighCape’s Annual
Report on Form 10-K for the year ended December 31, 2020 and the
proxy statement/prospectus relating to the Business Combination,
including those under “Risk Factors” therein, and in HighCape’s
other filings with the SEC. HighCape and Quantum-Si caution that
the foregoing list of factors is not exclusive. HighCape and
Quantum-Si caution readers not to place undue reliance upon any
forward-looking statements, which speak only as of the date made.
HighCape and Quantum-Si do not undertake or accept any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based.
No Offer or Solicitation
This press release shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the Business Combination. This press release shall
also not constitute an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of
securities in any states or jurisdictions in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of section 10 of the Securities
Act of 1933, as amended, or an exemption therefrom.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210506005394/en/
Investor Relations Mike Cavanaugh or Mark Klausner
Westwicke, an ICR Company (646) 677-1838 QSI-IR@westwicke.com
Media Relations Cammy Duong Westwicke, an ICR Company
(203) 682-8380 QSI-PR@westwicke.com
HighCape Capital Acquisi... (NASDAQ:CAPA)
Historical Stock Chart
From Feb 2025 to Mar 2025
HighCape Capital Acquisi... (NASDAQ:CAPA)
Historical Stock Chart
From Mar 2024 to Mar 2025
